Since 1987
REVIEW OF CLINICAL PHARMACOLOGY AND PHARMACOKINETICS, INTERNATIONAL EDITION | 38 (1): 10 (2024) Rcpp

https://doi.org/10.61873/FVLX2571

ERRATUM

Erratum to: Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen?

Georgios Iatrakis[1], Stefanos Zervoudis[1,2], Angeliki Sarella[1], Panagiotis Tsikouras[3], Minas Paschopoulos[5], Myrsini Balafouta[1], Panagiotis Peitsidis [4,*]

[1] University of West Attica, Athens, Greece
[2] Rea Hospital, Athens, Greece
[3] University Hospital of Alexandroupolis, Greece
[4] Helena Venizelou Hospital Athens, Greece
[5] University of Ioannina, Greece

***Corresponding author**
Dr. Panagiotis Peitsidis PhD Msc, Obstetrician Gynecologist, Helena Venizelou Hospital Athens, Greece
Email: peitsidiobgyn@gmail.com

Published online: 11 March 2024
©PHARMAKON-Press

Erratum to: Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(1): 7-9 (2024). https://doi.org/10.61873/OEFM7580

Due to an unfortunate oversight of the corresponding author, Anastasia Bothou was included as an author of the editorial without her consent and knowledge. The citation of the editorial has now been amended as follows: Iatrakis G., Zervoudis S., Sarella A., Tsikouras P., Paschopoulos M., Balafouta M., Peitsidis P. Should ultrasound assessment of the endometrium be necessary in patients treated with Tamoxifen? Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(1): 7-9 (2024). https://doi.org/10.61873/OEFM7580. The publisher will update the PDF and HTML versions of the paper on the journal's website, and will alert downstream indexes and databases through supplying updated metadata.

The online version of the original article can be found under https://doi.org/10.61873/OEFM7580